INTRODUCTION: To date, there are no guidelines for a rational and more favourable sequence of treatment after docetaxel.
Two drugs (cabazitaxel and abiraterone) have recently been approved as second-line treatment after docetaxel failure in metastatic castration-resistant prostate cancer (mCRPC), but there are no studies comparing abiraterone versus cabazitaxel. The most suitable drug is chosen based on the physician's opinion and the patient's characteristics. In patients with a good performance status who are able to receive either treatment, it would be convenient to begin with cabazitaxel and to reserve abiraterone in case there is a worsening of the general status, in consideration of abiraterone's more favourable toxicity profile.
CASE REPORT: We describe the case of a 74-year-old male with mCRPC who presented with an interesting and uncommon tumour dissemination (pleuropulmonary) occurring after the first standard treatment with docetaxel. Intravenous treatment with cabazitaxel 25 mg/m2 and oral prednisone 10 mg continuously was initiated. The patient received a total of 8 cycles of chemotherapy. A reduction of mediastinal adenopathies and infrarenal para-aortic stable bone involvement and an absence of pleural effusion were observed. No relevant toxicity was noted. Since February 2012, a progressive PSA increase without clinical deterioration has been noted.
CONCLUSIONS: The selection criteria for second- and third-line systemic treatment and the excellent response obtained with cabazitaxel in an unusual disease setting are described. The results confirm the long duration and quality of response of cabazitaxel treatment. Further therapeutic options in this group of patients are suggested.
Written by:
Huerta AS, Santos ER, Campos GB, Coloma CS, Gómez ON. Are you the author?
Medical Oncology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Reference: Case Rep Oncol. 2013 Jul 20;6(2):391-6.
doi: 10.1159/000354089
PubMed Abstract
PMID: 23904851
UroToday.com mCRPC Treatment Section
